Efficacy of a Modified Live Virus Vaccine against Porcine Reproductive and Respiratory Syndrome Virus 1 (PRRSV-1) Administered to 1-Day-Old Piglets in Front of Heterologous PRRSV-1 Challenge

PRRSV is one of the most important viruses in the global swine industry and is often controlled by the use of modified live virus (MLV) vaccines. This study assessed the impact of a PRRSV-1 MLV vaccine applied to 1-day-old piglets challenged on day 28 of life with a PRRSV-1 field isolate (AUT15-33). Twenty-one piglets were vaccinated within 24 h of birth (T02), whereas 20 piglets were left unvaccinated (T01). Necropsy was performed two weeks post-challenge. Comparing the two groups, T02 piglets showed significantly higher (p = 0.017) average daily weight gain. In addition, significantly lower (p < 0.0001) PRRSV RNA loads were measured in serum of T02 piglets at all investigated time points. All T01 piglets were viremic and shed virus in nasal swabs, whereas only 71.4 % and 38.1 % of the T02 group were viremic or shed virus, respectively. Piglets from T02 had significantly higher numbers (p < 0.0001) of IFN-γ producing lymphocytes compared to T01. At necropsy, differences in gross and histologic lung lesions were statistically significant (p = 0.012 and p < 0.0001, respectively) between the two groups. Hence, this MLV vaccine administered to 1-day-old piglets was able to protect piglets against PRRSV infection at weaning.

PATHOMORPHOLOGY, DIAGNOSTICS AND SPECIFIC PREVENTION OF VIRAL RESPIRATORY AND ABOMASOENTERITIC INFECTIONS IN CALVES

Viral diseases in calves are common and often occur in associations. Pathomorphological changes in organs and tissues at viral infections allow making a preliminary nosological diagnosis and develop therapeutic and preventive measures to eliminate diseases. A single immunization of cows with a live-virus vaccine by the “carpet method” prevents the infection of calves in utero, and increases the safety rate of newborn calves.

93 Genomic basis of antibody response to porcine reproductive and respiratory syndrome virus vaccination

Antibody (Ab) response to natural infection with porcine reproductive and respiratory syndrome (PRRS) virus has been shown to be highly heritable (~0.40), to be genetically correlated with farrowing performance in PRRSV-infected sows, be controlled by two major QTL on chromosome 7, among others, and have moderate genomic prediction accuracy. However, waiting for PRRS outbreaks to occur to collect data limits the use of Ab response to select for increased PRRS resilience. Thus, we investigated the genomic basis of Ab response to PRRS vaccination with a modified live PRRSV vaccine as a strategy to generate data for this purpose. Nine hundred and six commercial F1 replacement gilts (189±16 days old) were vaccinated with a commercial PRRS modified live virus vaccine. Blood samples were collected 52 days after vaccination to measure Ab response, as sample-to-positive (S/P) ratio using a commercial ELISA, and for SNP genotyping (~50K). BayesC0 was used to estimate heritability for S/P ratio using in a model with contemporary group (CG) as fixed effect and SNP effects as random. Genome-wide association study and genomic prediction for S/P ratio were performed with BayesB (Pi=0.99). For genomic prediction, a three-fold cross-validation was used, in which each CG (n=3) was used as validation dataset. Accuracy of genomic prediction was defined as the correlation between genomic estimated breeding values and phenotypes adjusted for estimates of fixed effects, weighed by the number of individuals in the validation dataset. Heritability of S/P was moderate (0.35±0.04). A QTL was identified on chromosome 7 (25 Mb) explaining ~28% of the genetic variance. Accuracy of genomic prediction was fairly high (0.60±0.15). This is the first study describing the genomic basis of Ab response to PRRS vaccination with modified-live virus vaccine. Additional work is needed to evaluate the genetic correlation of Ab response to vaccination with resilience traits in pigs.

Development of an innovative delivery system for bacillus Calmette-Guérin bladder administration

Purpose To describe the development of an innovative process to deliver bacillus Calmette-Guérin (BCG) to an offsite urology clinic for bladder instillation. Summary The use of BCG, a live virus vaccine for treatment of patients with localized cancer of the urinary bladder, has created many logistical problems for hospitals and infusion center pharmacies. Due to its short stability, the drug cannot be made ahead of time and coordination with a patient’s arrival at an infusion site is challenging. This becomes exceptionally challenging when a urology clinic has limited compounding capacity and/or is distant from the site of BCG medication preparation. This article describes an innovative process involving use of closed-system transfer devices (CSTDs) to allow for the administration of BCG in a urology clinic offsite from a medical center’s infusion center facilities. Conclusion The use of the CSTD allowed the patients to continue to receive bladder instillations at an offsite urology clinic without significantly disrupting compounding workflow at the small infusion center pharmacy that was the nearest to the clinic.

Field safety and efficacy of a unique live virus vaccine for controlling avian encephalomyelitis and fowlpox in poultry

Background and Aim: Infection of commercial poultry with avian encephalomyelitis (AE) and fowlpox (FP) virus causes heavy economic loss in endemic areas. Although vaccines are routinely used to control these two diseases, the problem still persists almost all over the world. This study aimed to evaluate safety and efficacy of a unique AE + FP + pigeon pox (PP) live virus vaccine in layer-type chickens under both laboratory and field conditions. Materials and Methods: The study was conducted using 289 specific-pathogen-free (SPF) chickens under the laboratory conditions and 185,648 commercial layer-type chickens under field conditions. In two consecutive laboratory trials, 8-week-old SPF chickens were vaccinated with the AE + FP + PP live virus vaccine through wing web route and challenged against virulent strains of FP and AE viruses at 3-week post-vaccination (WPV). Challenged chickens were observed for disease protection for 10-21 days. For field safety trials, commercial layer-type chickens in three different geographical areas in the USA were vaccinated with the AE + FP + PP vaccine and observed daily up to 21 days for vaccine "take". adverse reactions, and mortality. Results: The vaccine was found safe and efficacious under both laboratory and field conditions. Vaccine "take" and protection against FP challenge were 100%. Average protection against AE challenge was 97%. Mean AE enzyme-linked immunosorbent assay (ELISA) antibody titer in the field vaccinated chickens was >1200 at 10 WPV. Average daily post-vaccination mortality in the field vaccinated chickens was 0.04%. So far, more than 400 million chickens in the USA have been vaccinated with this vaccine. No vaccine-associated adverse reactions, other safety issues, or immunity breakdown cases in the vaccinated flocks due to field virus infection have been reported. Conclusion: This unique vaccine containing AE, FP, and PP viruses in a single preparation was found to be safe and efficacious in controlling the diseases caused by the virulent field strains of AE and FP. Besides being safe and efficacious, this vaccine also offered distinct advantages over the traditional vaccination practices in controlling these two diseases in poultry. Keywords: avian encephalomyelitis, efficacy, field safety, fowlpox, live virus vaccine, pigeon pox, protection.